To mark the first ever World Lewy Body Day on 28 January 2024, Dr Daniel Erskine explains how his research is helping us understand more about dementia with Lewy bodies so we can get closer to a cure.
Three key take-aways from this year’s Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston
Our Executive Director of Research and Partnerships, Dr Susan Kohlhaas, reflects back on the Clinical Trials in Alzheimer’s Disease (CTAD) conference and shares her excitement about what’s to come for dementia research.
Alzheimer’s Research UK’s experts discuss what we know so far about frontotemporal dementia (FTD).
Lots of factors affect a person’s risk of getting Alzheimer’s disease, the number one cause of dementia. It’s a complex mix of lifestyle, health and age, but our genetic makeup plays a particularly important role in determining whether we will get Alzheimer’s.
Researchers at University College London (UCL) are studying a unique group of volunteers to find out how lifelong factors affect brain health
30 years ago Prof John Hardy set out the amyloid cascade hypothesis, giving the foundation for our current understanding of Alzheimer’s.
Mike Oldham has joined Alzheimer’s Research UK as our new Director of EDoN. We caught up with Mike to find out more about his background and the work he will be doing at Alzheimer’s Research UK. What has been your career path to date? I’m an aeronautical engineer by training, spending the first part…
Today is a historic day for dementia research with the US Food and Drug Administration (FDA) announcing the first (conditional) licence of a new drug for Alzheimer’s disease in a generation.
At Alzheimer’s Research UK, we are committed to finding treatments that slow or stop the diseases that cause dementia.
We won’t stop until we find them.
When someone receives a diagnosis of dementia, little is known about how their condition will progress and affect that individual over time. This is because dementia affects every person differently, with a number of factors influencing progression such as having other health conditions, our level of cognitive reserve and whether a person takes medications to treat other conditions.